Last Updated On 01 February 2022 2 Min Read
Aspen Pharmacare looking good at the price, say analysts
The pharmaceutical group expects Heps to rise more than a third in its 2022 half year, benefiting from lower finance costs
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In